Helix BioPharma Corp. announced the addition of three new members to its Board of Directors (the "Board"). Jerzy Leszczynski, Christopher Maciejewski and Jacek Antas have been appointed to the Board effective immediately.

These appointments are designed to improve the Company's independence, diversification and corporate governance with an aim of strengthening the Company's future growth capabilities. Jerzy Leszczynski is a shareholder of the Company, has spent more than 35 years developing businesses and has served in the capacity of board member of various real estate development companies. Mr. Leszczynski obtained his Masters of Science in Chemistry from the Warsaw Institute of Technology.

Christopher Maciejewski is a consultant to an international flight medicine transport service. Prior to this role, Mr. Maciejewsi served as the Chief Medical Officer of MedEvac Canada, a leading non-emergency patient transfer company. He has spent more than thirty years building and leading businesses in medical field, specifically within air ambulance transport.

Mr. Maciejewski has an extensive educational background and attended Silesian University in Wroclaw, Poland where he studied Applied Medical Manual Sciences. Mr. Maciejewski is based in Toronto, Ontario, Canada. Jacek Antas has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master's degree from the Warsaw School of Economics and has served as a board member of various companies throughout his career.